<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//Atypon//DTD Atypon Systems Journal Archiving and Interchange NLM DTD v3.0.6 20130326//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName atypon-archivearticle3.dtd?><?SourceDTD.Version 3.0.6?><?ConverterInfo.XSLTName atyponoasis-oasisns2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Neurotrauma</journal-id><journal-id journal-id-type="iso-abbrev">J. Neurotrauma</journal-id><journal-id journal-id-type="publisher-id">neu</journal-id><journal-title-group><journal-title>Journal of Neurotrauma</journal-title></journal-title-group><issn pub-type="ppub">0897-7151</issn><issn pub-type="epub">1557-9042</issn><publisher><publisher-name>Mary Ann Liebert, Inc.</publisher-name><publisher-loc>140 Huguenot Street, 3rd FloorNew Rochelle, NY 10801USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5510669</article-id><article-id pub-id-type="pmid">28287909</article-id><article-id pub-id-type="publisher-id">10.1089/neu.2016.4869</article-id><article-id pub-id-type="doi">10.1089/neu.2016.4869</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title><SecTag type="TITLE"><text><SENT sid="0" pm="."><plain>Clinical Evaluation of a Microwave-Based Device for Detection of Traumatic Intracranial Hemorrhage </plain></SENT>
</text></SecTag></article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Ljungqvist</surname><given-names>Johan</given-names></name><xref ref-type="aff" rid="aff1"><sup>1,</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" corresp="yes"><name><surname>Candefjord</surname><given-names>Stefan</given-names></name><xref ref-type="aff" rid="aff3"><sup>3,</sup></xref><xref ref-type="aff" rid="aff4"><sup>4,</sup></xref><xref ref-type="aff" rid="aff5"><sup>5</sup></xref></contrib><contrib contrib-type="author"><name><surname>Persson</surname><given-names>Mikael</given-names></name><xref ref-type="aff" rid="aff3"><sup>3,</sup></xref><xref ref-type="aff" rid="aff4"><sup>4</sup></xref></contrib><contrib contrib-type="author"><name><surname>Jönsson</surname><given-names>Lars</given-names></name><xref ref-type="aff" rid="aff6"><sup>6</sup></xref></contrib><contrib contrib-type="author"><name><surname>Skoglund</surname><given-names>Thomas</given-names></name><xref ref-type="aff" rid="aff1"><sup>1,</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Elam</surname><given-names>Mikael</given-names></name><xref ref-type="aff" rid="aff4"><sup>4,</sup></xref><xref ref-type="aff" rid="aff7"><sup>7</sup></xref></contrib><aff id="aff1"><label><sup>1</sup></label>Department of Neurosurgery, <institution>Sahlgrenska University Hospital</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff2"><label><sup>2</sup></label>Institute of Neuroscience and Physiology, Department of Clinical Neuroscience, <institution>The Sahlgrenska Academy at the University of Gothenburg</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff3"><label><sup>3</sup></label>Department of Signals and Systems, <institution>Chalmers University of Technology</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff4"><label><sup>4</sup></label>MedTech West, <institution>Sahlgrenska University Hospital</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff5"><label><sup>5</sup></label><institution>SAFER Vehicle and Traffic Safety Centre at Chalmers</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff6"><label><sup>6</sup></label>Department of Neuroradiology, <institution>Sahlgrenska University Hospital</institution>, Gothenburg, <country>Sweden</country>.</aff><aff id="aff7"><label><sup>7</sup></label>Department of Clinical Neurophysiology, <institution>Sahlgrenska University Hospital</institution>, Gothenburg, <country>Sweden</country>.</aff></contrib-group><author-notes><corresp><addr-line>Address correspondence to:</addr-line><addr-line><italic>Johan Ljungqvist, MD</italic></addr-line><addr-line><italic>Department of Neurosurgery</italic></addr-line><institution><italic>Sahlgrenska University Hospital</italic></institution><addr-line><italic>SE-413 45, Goteborg</italic></addr-line><country>Sweden</country><break/><italic>E-mail:</italic><email xlink:href="mailto:johan.ljungqvist@vgregion.se">johan.ljungqvist@vgregion.se</email></corresp></author-notes><pub-date pub-type="ppub"><day>01</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>01</day><month>7</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>01</day><month>7</month><year>2017</year></pub-date><volume>34</volume><issue>13</issue><fpage>2176</fpage><lpage>2182</lpage><permissions><copyright-statement>© Johan Ljungqvist et al., 2017; Published by Mary Ann Liebert, Inc.</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access"><license-p>This Open Access article is distributed under the terms of the Creative Commons License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="neu.2016.4869.pdf"/><abstract><title><text><SENT sid="1" pm="."><plain>Abstract </plain></SENT>
</text></title><p><SecTag type="ABS"><text><SENT sid="2" pm="."><plain>Traumatic brain injury (TBI) is the leading cause of death and disability among young persons. </plain></SENT>
<SENT sid="3" pm="."><plain>A key to improve outcome for patients with TBI is to reduce the time from injury to definitive care by achieving high triage accuracy. </plain></SENT>
<SENT sid="4" pm="."><plain>Microwave technology (MWT) allows for a portable device to be used in the pre-hospital setting for detection of intracranial hematomas at the scene of injury, thereby enhancing early triage and allowing for more adequate early care. </plain></SENT>
<SENT sid="5" pm="."><plain>MWT has previously been evaluated for medical applications including the ability to differentiate between hemorrhagic and ischemic stroke. </plain></SENT>
<SENT sid="6" pm="."><plain>The purpose of this study was to test whether MWT in conjunction with a diagnostic mathematical algorithm could be used as a medical screening tool to differentiate patients with traumatic intracranial hematomas, chronic subdural hematomas (cSDH), from a healthy control (HC) group. </plain></SENT>
<SENT sid="7" pm="."><plain>Twenty patients with cSDH and 20 HC were measured with a MWT device. </plain></SENT>
<SENT sid="8" pm="."><plain>The accuracy of the diagnostic algorithm was assessed using a leave-one-out analysis. </plain></SENT>
<SENT sid="9" pm="."><plain>At 100% sensitivity, the specificity was 75%—i.e., all hematomas were detected at the cost of 25% false positives (patients who would be overtriaged). </plain></SENT>
<SENT sid="10" pm="."><plain>Considering the need for methods to identify patients with intracranial hematomas in the pre-hospital setting, MWT shows promise as a tool to improve triage accuracy. </plain></SENT>
<SENT sid="11" pm="."><plain>Further studies are under way to evaluate MWT in patients with other intracranial hemorrhages. </plain></SENT>
</text></SecTag></p></abstract><SecTag type="KEYWORD"><kwd-group kwd-group-type="author"><title><bold>Keywords:</bold> </title><kwd>chronic subdural hematoma</kwd><kwd>intracranial hemorrhage detection</kwd><kwd>microwave technology</kwd><kwd>traumatic brain injury</kwd><kwd>triage</kwd></kwd-group></SecTag><counts><fig-count count="5"/><table-count count="3"/><ref-count count="28"/><page-count count="7"/></counts></article-meta></front><body><SecTag type="INTRO"><sec sec-type="intro" id="s001"><title><text><SENT sid="12" pm="."><plain>Introduction </plain></SENT>
</text></title><p><text><SENT sid="13" pm="."><plain>Early detection and evacuation of space-occupying intracranial hematomas is one of the cornerstones in the treatment of patients with traumatic brain injury (TBI). </plain></SENT>
<SENT sid="14" pm="."><plain>Seelig and associates1 showed that in patients with traumatic acute subdural hematomas, the delay from injury to operation was the factor of greatest therapeutic importance. </plain></SENT>
<SENT sid="15" pm="."><plain>Diagnosis and removal of the hematoma within four hours of injury considerably reduced death—i.e., from 90% to 30% mortality rate (n = 82, p &lt; 0.0001). </plain></SENT>
<SENT sid="16" pm="."><plain>Any further delay in hematoma evacuation severely increased death and worsened functional outcome in the patients who survived.1 </plain></SENT>
</text></p><p><text><SENT sid="17" pm="."><plain>A key to improve outcome for patients with TBI is to reduce the time to definitive care by achieving high triage accuracy. </plain></SENT>
<SENT sid="18" pm="."><plain>Unfortunately, this is not always attained in contemporary emergency care. </plain></SENT>
<SENT sid="19" pm="."><plain>Xiang and colleagues2 showed that more than one third of patients with major trauma (Injury Severity Score [ISS] ≥16) in the United States were undertriaged, with TBI constituting &gt;40% of undertriaged diagnoses, and intracranial hemorrhage being top-ranked. </plain></SENT>
<SENT sid="20" pm="."><plain>Haas and coworkers3 showed that death was almost 25% higher for patients transported to a non-trauma center compared with direct transport to a trauma center (n = 11,398, odds ratio 95%, confidence interval 1.10–1.40). </plain></SENT>
<SENT sid="21" pm="."><plain>Transporting all patients with suspected TBI to a center with neurosurgical expertise, however, results in substantial overtriage, which addresses the need for reliable TBI diagnosis at the scene of injury.4 </plain></SENT>
</text></p><p><text><SENT sid="22" pm="."><plain>Computed tomography (CT) is the gold standard for detection of intracranial hematomas. </plain></SENT>
<SENT sid="23" pm="."><plain>In most cases, however, the patient must wait until arrival at a hospital with access to radiology facilities before a CT scan can be performed. </plain></SENT>
<SENT sid="24" pm="."><plain>A compact system that can detect intracranial hemorrhage in a pre-hospital setting—e.g., in road and air ambulances—could improve triage accuracy and reduce the time between injury and operation, resulting in reduced mortality rates and improved functional outcomes. </plain></SENT>
<SENT sid="25" pm="."><plain>Several different technologies have been investigated with the aim to develop such a system.5–8 </plain></SENT>
</text></p><p><text><SENT sid="26" pm="."><plain>Microwave technology (MWT) for biomedical applications has been explored for more than three decades.9 Driving forces include the potential to realize portable devices at low cost to convey diagnostic information in a fast, non-invasive, and safe manner. </plain></SENT>
<SENT sid="27" pm="."><plain>This can be accomplished by employing non-ionizing microwave radiation with low power in conjunction with effective mathematical algorithms for signal processing. </plain></SENT>
<SENT sid="28" pm="."><plain>Because of the scattering nature of microwaves propagating in inhomogeneous media such as tissue, computationally demanding algorithms are required to process the data. </plain></SENT>
<SENT sid="29" pm="."><plain>Previous lack of sufficient computational power is one reason for the delay in introducing MTW in clinical settings. </plain></SENT>
</text></p><p><text><SENT sid="30" pm="."><plain>During the last decade, clinically relevant results have been realized, mainly for breast cancer.10–12 MWT can detect lesions such as cancer and internal bleedings because of the dielectric contrast between tissue types.13,14 For detection of intracranial hemorrhage, the contrast between blood and brain matter is utilized.15 In neurosurgical care, MWT could be used to monitor patients with conservatively managed hematomas, to monitor patients post-operatively, and to monitor patients with trauma in neurointensive care who are at risk of progressing contusions or extracerebral hematomas. </plain></SENT>
</text></p><p><text><SENT sid="31" pm="."><plain>Recently, Persson and associates15 showed that MWT can differentiate hemorrhagic and ischemic stroke. </plain></SENT>
<SENT sid="32" pm="."><plain>They used two MWT prototype systems to measure 20 and 25 stroke patients, respectively, in the first two proof-of-principle clinical studies. </plain></SENT>
<SENT sid="33" pm="."><plain>A machine-learning approach was used to differentiate the two patient groups—i.e., a classifier was derived from supervised (patient diagnosis is known) training on the patient measurements and evaluated using a so-called leave-one-out (LOO) analysis. </plain></SENT>
</text></p><p><text><SENT sid="34" pm="."><plain>Encouraging results were presented, achieving areas under the receiver operating characteristic (ROC) curve (AUC) of 0.88 and 0.85 for the first and second clinical trial, respectively. </plain></SENT>
<SENT sid="35" pm="."><plain>Sensitivity and specificity depend on the classifier threshold (decision offset). </plain></SENT>
<SENT sid="36" pm="."><plain>For example, at 90% sensitivity for detection of hemorrhagic stroke, the specificity was 65% for the second clinical study.15 The ability of a device to differentiate hemorrhagic and ischemic stroke in the pre-hospital setting could allow for rapid thrombolytic therapy in patients with ischemia and more adequate care for patients with intracerebral hematomas. </plain></SENT>
</text></p><p><text><SENT sid="37" pm="."><plain>The purpose of the current clinical investigation was to test whether MWT, using the first portable device enabling pre-hospital measurements, could be used as a medical screening tool to differentiate patients with a traumatic intracranial hematoma from a healthy control (HC) group. </plain></SENT>
<SENT sid="38" pm="."><plain>Because this is the first study using MWT to examine patients with trauma, we chose to include patients with chronic subdural hematomas (cSDH), which is an intracranial hemorrhage usually not necessitating immediate management. </plain></SENT>
<SENT sid="39" pm="."><plain>A cSDH is a collection of blood and blood breakdown products between the surface of the brain and the dura. </plain></SENT>
<SENT sid="40" pm="."><plain>It is often caused by a minor head injury, expands slowly, and symptoms can take weeks to appear.16 Large or symptomatic hematomas are usually considered indications for surgical evacuation.16 By studying patients with cSDH, we aimed to test the viability of MWT for hematoma detection, in terms of sensitivity and specificity, compared to the CT scan as the gold standard. </plain></SENT>
</text></p></sec></SecTag><SecTag type="METHODS"><sec sec-type="subjects" id="s002"><title><text><SENT sid="41" pm="."><plain>Patients and Methods </plain></SENT>
</text></title><sec id="s003"><title><text><SENT sid="42" pm="."><plain>Study subjects </plain></SENT>
</text></title><p><text><SENT sid="43" pm="."><plain>This study was approved by the Regional Ethical Review Board at the University of Gothenburg, Sweden, and reviewed by The Medical Products Agency - Sweden. </plain></SENT>
<SENT sid="44" pm="."><plain>It was conducted according to Good Clinical Practice, the revised Declaration of Helsinki, and the ISO 14155:2011 standard. </plain></SENT>
<SENT sid="45" pm="."><plain>The study was registered at ClinicalTrials.gov (Identifier: NCT02282228) before the recruitment of the first study participant. </plain></SENT>
</text></p><p><text><SENT sid="46" pm="."><plain>All patients were referred to Sahlgrenska University Hospital for operation of cSDH, during the period September 2015 to January 2016. </plain></SENT>
<SENT sid="47" pm="."><plain>The HC group was recruited in the same period as the patients and matched to the patient cohort for age and sex. </plain></SENT>
<SENT sid="48" pm="."><plain>Written informed consent was obtained from all participants before any study-related procedure was initiated. </plain></SENT>
<SENT sid="49" pm="."><plain>Safety follow-up for participants was performed &gt;12 h after the diagnostic procedure. </plain></SENT>
<SENT sid="50" pm="."><plain>The inclusion and exclusion criteria are shown in Table 1. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T1" orientation="portrait" position="float"><label><sc>Table</sc> 1.</label><caption><p><text><SENT sid="51" pm="."><plain>Inclusion and Exclusion Criteria for Patients and Controls </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th align="left"><text><SENT sid="52" pm="."><plain>Inclusion criteria patients </plain></SENT>
</text></th><th align="center"><text><SENT sid="53" pm="."><plain>Inclusion criteria controls </plain></SENT>
</text></th><th align="center"><text><SENT sid="54" pm="."><plain>Exclusion criteria patients and controls </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="55" pm="."><plain>Admitted for surgery of cSDH </plain></SENT>
</text></td><td align="left"><text><SENT sid="56" pm="."><plain>Healthy—i.e., no significant medical history </plain></SENT>
</text></td><td align="left"><text><SENT sid="57" pm="."><plain>Pregnant or breastfeeding women </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="58" pm="."><plain>CT brain scan within 96 h </plain></SENT>
</text></td><td align="left"><text><SENT sid="59" pm="."><plain>≥18 years of age </plain></SENT>
</text></td><td align="left"><text><SENT sid="60" pm="."><plain>Shunt or other foreign object implanted in the brain </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="61" pm="."><plain>≥18 years of age </plain></SENT>
</text></td><td align="left"><text><SENT sid="62" pm="."><plain>Signed a written informed consent </plain></SENT>
</text></td><td align="left"><text><SENT sid="63" pm="."><plain>Participation in any other clinical study that could interfere with the result in the ongoing study </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="64" pm="."><plain>Be able to have a normal conversation and understand the information about the study, corresponding to Glasgow Coma Scale (Verbal Response) of 5 </plain></SENT>
</text></td><td align="left"><text><SENT sid="65" pm="."><plain>  </plain></SENT>
</text></td><td align="left"><text><SENT sid="66" pm="."><plain>  </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="67" pm="."><plain>Signed a written informed consent </plain></SENT>
</text></td><td align="left"><text><SENT sid="68" pm="."><plain>  </plain></SENT>
</text></td><td align="left"><text><SENT sid="69" pm="."><plain>  </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tf1"><p><text><SENT sid="70" pm="."><plain>cSDH, chronic subdural hematoma; CT, computed tomography. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec><sec id="s004"><title><text><SENT sid="71" pm="."><plain>Measurements </plain></SENT>
</text></title><p><text><SENT sid="72" pm="."><plain>Eligible patients were included in the study on arrival at the neurosurgical unit. </plain></SENT>
<SENT sid="73" pm="."><plain>They were measured with the microwave device (Strokefinder MD100, Medfield Diagnostics AB, Gothenburg, Sweden) before operation of cSDH. </plain></SENT>
<SENT sid="74" pm="."><plain>Measurements were performed with the subjects lying in a hospital bed. </plain></SENT>
<SENT sid="75" pm="."><plain>A thin disposable plastic protective cover (evercare® Banded Bag - REF 1855 - Ø 140 cm, OneMed Group Oy, Helsinki, Finland) was mounted around the device for hygienic reasons before the subject's head was positioned in the device. </plain></SENT>
<SENT sid="76" pm="."><plain>The subjects were required to lie still for the duration of the measurement (approximately 45 sec). </plain></SENT>
<SENT sid="77" pm="."><plain>No significant movements were visually observed during any subject measurements. </plain></SENT>
<SENT sid="78" pm="."><plain>Two investigators performed all measurements. </plain></SENT>
</text></p><p><text><SENT sid="79" pm="."><plain>The Strokefinder MD100 is designed like a headrest for placement on a hospital bed or ambulance stretcher (Fig. 1). </plain></SENT>
<SENT sid="80" pm="."><plain>The device has eight antennas mounted in four pairs, where the pair in contact with the back of the patient's head is mounted at the bottom, and the other three pairs are mounted on separate arms. </plain></SENT>
<SENT sid="81" pm="."><plain>When the patient's head has been positioned in the device, the fastening mechanism is tightened until sufficient antenna contact with the head is achieved, without causing discomfort to the subject. </plain></SENT>
<SENT sid="82" pm="."><plain>The investigators followed a standardized procedure to position the patient's head, and carefully inspected that the head was placed symmetrically in the device. </plain></SENT>
<SENT sid="83" pm="."><plain>The measurements were started from a tablet computer, which was connected wirelessly to the main unit. </plain></SENT>
<SENT sid="84" pm="."><plain>The proprietary software included a test verifying that all antennas achieved good contact with the subject's head. </plain></SENT>
<SENT sid="85" pm="."><plain>If the test showed that one or more antennas did not achieve good contact, the subject's head was repositioned and the antenna positions and contact pressure controlled until the test was approved. </plain></SENT>
<SENT sid="86" pm="."><plain>The device automatically performed three consecutive measurements during the diagnostic procedure. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 1.</bold></label><caption><p><text><SENT sid="87" pm="."><plain>The Strokefinder MD100 device (Medfield Diagnostics AB, Gothenburg, Sweden). </plain></SENT>
<SENT sid="88" pm="."><plain>Reprinted with permission. </plain></SENT>
</text></p></caption><graphic xlink:href="fig-1"/></fig></SecTag></sec><sec id="s005"><title><text><SENT sid="89" pm="."><plain>CT-scan assessment </plain></SENT>
</text></title><p><text><SENT sid="90" pm="."><plain>The patients' CT-scans were reviewed. </plain></SENT>
<SENT sid="91" pm="."><plain>Volume and attenuation of the hematomas and midline shift were measured. </plain></SENT>
<SENT sid="92" pm="."><plain>The volume of the hematomas was estimated by delineating the hematomas manually using the ITK-SNAP software (Version 3.4.0, University of Pennsylvania), and the software then automatically calculated the volume. </plain></SENT>
<SENT sid="93" pm="."><plain>A neuroradiologist (author LJ) then measured the attenuation of the hematomas and confirmed the accuracy of the volume and midline shift measurements. </plain></SENT>
</text></p></sec><sec id="s006"><title><text><SENT sid="94" pm="."><plain>Microwave data pre-processing and analysis </plain></SENT>
</text></title><p><text><SENT sid="95" pm="."><plain>The raw microwave data consisted of all antenna combinations (channels), including both reflection channels (same antenna sending and receiving) and transmission channels (one antenna sending, the other antennas receiving). </plain></SENT>
<SENT sid="96" pm="."><plain>The full frequency range was approximately 0.1–1.95 GHz. </plain></SENT>
<SENT sid="97" pm="."><plain>The raw data were pre-processed—i.e., prepared and transformed into a format suitable for the diagnostic algorithm, by excluding channels with high attenuation (i.e., low signal-to-noise ratio, because of a relatively long direct path through the brain) and channels that measured more peripheral regions relative to the commonly lateral location of cSDH. Figure 2 illustrates the excluded channels. </plain></SENT>
<SENT sid="98" pm="."><plain>For each measurement, all selected frequencies of the retained channels were combined into one complex vector. </plain></SENT>
<SENT sid="99" pm="."><plain>The three measurements on each subject were averaged into one mean measurement. </plain></SENT>
<SENT sid="100" pm="."><plain>No further pre-processing of the raw data was performed. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 2.</bold></label><caption><p><text><SENT sid="101" pm="."><plain>The reflection and transmission coefficients for antennas 1 and 2 (at subject's forehead) and antennas 7 and 8 (at back of subject's head) were removed, except for channels between the lateral antennas (3 to 6) and forehead/back of head antennas. </plain></SENT>
<SENT sid="102" pm="."><plain>The dashed lines indicate the channels that were removed. </plain></SENT>
</text></p></caption><graphic xlink:href="fig-2"/></fig></SecTag><p><text><SENT sid="103" pm="."><plain>The classifier developed by Persson and coworkers15 was used on the pre-processed data. </plain></SENT>
<SENT sid="104" pm="."><plain>A LOO cross-validation procedure was used—i.e., the subject measurement to be classified was not included in the training data—to avoid overfitting. </plain></SENT>
<SENT sid="105" pm="."><plain>The classifier performance depends on which so-called subspace dimensions are retained.15 A repeated LOO procedure was used to identify the subspace dimensions and frequency interval that yielded optimal classifier performance. </plain></SENT>
</text></p><p><text><SENT sid="106" pm="."><plain>The diagnostic performance was evaluated using the ROC and the AUC. </plain></SENT>
<SENT sid="107" pm="."><plain>An AUC of ∼0.5 represents a useless diagnostic test, equal to relying on chance. </plain></SENT>
<SENT sid="108" pm="."><plain>An AUC of 1.0 represents a perfect test that classifies all subjects correctly. </plain></SENT>
<SENT sid="109" pm="."><plain>The specificity at 100% sensitivity was derived from the ROC. </plain></SENT>
<SENT sid="110" pm="."><plain>A scatter plot was used to show the classifier decision value for all subjects.15 The frequency was swept from 0.1–1.95 GHz with 50 MHz step-size and a minimum frequency interval of 400 MHz. </plain></SENT>
<SENT sid="111" pm="."><plain>The highest AUC on average for all frequency intervals was given by keeping only the first subspace dimension, and this classifier setting was therefore used throughout all tests in this study. </plain></SENT>
<SENT sid="112" pm="."><plain>The frequency interval 0.75–1.95 GHz yielded the highest specificity at 100% sensitivity and was therefore used throughout all tests in this study. </plain></SENT>
</text></p><p><text><SENT sid="113" pm="."><plain>To test the robustness of the classification with the selected pre-processing and classification parameter settings, 100 repeated LOO procedures were performed on data sets where a few random subjects were removed each time. </plain></SENT>
<SENT sid="114" pm="."><plain>We chose to remove two random subjects from the full data set for each iteration. </plain></SENT>
<SENT sid="115" pm="."><plain>The mean and standard deviation of the AUC were calculated from the 100 iterations. </plain></SENT>
<SENT sid="116" pm="."><plain>If the mean AUC is close to the AUC for the full data set and the standard deviation is relatively small, this indicates that the selected parameter settings for the classification are robust—i.e., the result does not fluctuate substantially depending on the exact configuration of the data set. </plain></SENT>
</text></p><p><text><SENT sid="117" pm="."><plain>To validate that the classifier did not become overfitted (model being fitted to irrelevant information/noise) to the data, 100 repeated LOO procedures were performed on data sets where the subjects were randomly assigned to one of the two classes—i.e., each subject was assigned to either the cSDH group or the HC group regardless of the true diagnosis. </plain></SENT>
<SENT sid="118" pm="."><plain>For such random data sets, it is expected that the groups cannot be differentiated—i.e., an AUC ∼0.5 is expected. </plain></SENT>
<SENT sid="119" pm="."><plain>It is a useful check for bias of the mathematical model, which would cause deviations from the expected performance.17 The mean and standard deviation of the AUC were calculated from the 100 iterations. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="RESULTS"><sec sec-type="results" id="s007"><title><text><SENT sid="120" pm="."><plain>Results </plain></SENT>
</text></title><p><text><SENT sid="121" pm="."><plain>Twenty patients with cSDH and 20 HC subjects were included in the study. Table 2 shows age, sex, main symptoms, hematoma volume, attenuation, and midline shift for the patients. </plain></SENT>
<SENT sid="122" pm="."><plain>Eight female and 12 male patients were included, and the mean age for the patients was 75.6 years (range 54–90 years). </plain></SENT>
<SENT sid="123" pm="."><plain>The HC group consisted of nine females and 11 males with a mean age of 71.8 years (range 61–82 years). Figure 3 shows a representative example of a CT scan of a patient with cSDH. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="f3" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 3.</bold></label><caption><p><text><SENT sid="124" pm="."><plain>A typical appearance of a cSDH on the left side (patient P3) on a computed tomography scan, with its characteristic crescent-shaped form spanning over the coronal and lambdoid sutural margins. </plain></SENT>
<SENT sid="125" pm="."><plain>The hematoma is in the hypodense phase. </plain></SENT>
<SENT sid="126" pm="."><plain>Notice also the significant midline shift. </plain></SENT>
</text></p></caption><graphic xlink:href="fig-3"/></fig></SecTag><SecTag type="TABLE"><table-wrap id="T2" orientation="portrait" position="float"><label><sc>Table</sc> 2.</label><caption><p><text><SENT sid="127" pm="."><plain>Characteristics of the Patients* </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th align="left"><text><SENT sid="128" pm="."><plain>  </plain></SENT>
</text></th><th align="left"><text><SENT sid="129" pm="."><plain>  </plain></SENT>
</text></th><th align="left"><text><SENT sid="130" pm="."><plain>  </plain></SENT>
</text></th><th align="left"><text><SENT sid="131" pm="."><plain>  </plain></SENT>
</text></th><th colspan="2" align="center"><text><SENT sid="132" pm="."><plain>Hematoma volume </plain></SENT>
</text></th><th align="left"><text><SENT sid="133" pm="."><plain>  </plain></SENT>
</text></th><th align="left"><text><SENT sid="134" pm="."><plain>  </plain></SENT>
</text></th></tr><tr><th align="left"><text><SENT sid="135" pm="."><plain>Patient </plain></SENT>
</text></th><th align="center"><text><SENT sid="136" pm="."><plain>Age (years) </plain></SENT>
</text></th><th align="center"><text><SENT sid="137" pm="."><plain>Sex (male/female) </plain></SENT>
</text></th><th align="center"><text><SENT sid="138" pm="."><plain>Main symptoms </plain></SENT>
</text></th><th align="center"><text><SENT sid="139" pm="."><plain>Right (mL) </plain></SENT>
</text></th><th align="center"><text><SENT sid="140" pm="."><plain>Left (mL) </plain></SENT>
</text></th><th align="center"><text><SENT sid="141" pm="."><plain>Attenuation (HU) </plain></SENT>
</text></th><th align="center"><text><SENT sid="142" pm="."><plain>Midline shift (mm) </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="143" pm="."><plain>P1 </plain></SENT>
</text></td><td align="center"><text><SENT sid="144" pm="."><plain>63 </plain></SENT>
</text></td><td align="left"><text><SENT sid="145" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="146" pm="."><plain>Hemiparesis left side. </plain></SENT>
<SENT sid="147" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="148" pm="."><plain>104 </plain></SENT>
</text></td><td align="center"><text><SENT sid="149" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="150" pm="."><plain>26 </plain></SENT>
</text></td><td align="center"><text><SENT sid="151" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="152" pm="."><plain>P2 </plain></SENT>
</text></td><td align="center"><text><SENT sid="153" pm="."><plain>90 </plain></SENT>
</text></td><td align="left"><text><SENT sid="154" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="155" pm="."><plain>Hemiparesis left side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="156" pm="."><plain>116 </plain></SENT>
</text></td><td align="center"><text><SENT sid="157" pm="."><plain>18 </plain></SENT>
</text></td><td align="center"><text><SENT sid="158" pm="."><plain>22–49 </plain></SENT>
</text></td><td align="center"><text><SENT sid="159" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="160" pm="."><plain>P3 </plain></SENT>
</text></td><td align="center"><text><SENT sid="161" pm="."><plain>81 </plain></SENT>
</text></td><td align="left"><text><SENT sid="162" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="163" pm="."><plain>Headache. </plain></SENT>
<SENT sid="164" pm="."><plain>Discrete dysphasia. </plain></SENT>
</text></td><td align="center"><text><SENT sid="165" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="166" pm="."><plain>174 </plain></SENT>
</text></td><td align="center"><text><SENT sid="167" pm="."><plain>26–49 </plain></SENT>
</text></td><td align="center"><text><SENT sid="168" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="169" pm="."><plain>P4 </plain></SENT>
</text></td><td align="center"><text><SENT sid="170" pm="."><plain>67 </plain></SENT>
</text></td><td align="left"><text><SENT sid="171" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="172" pm="."><plain>Headache. </plain></SENT>
<SENT sid="173" pm="."><plain>Disturbed balance. </plain></SENT>
</text></td><td align="center"><text><SENT sid="174" pm="."><plain>163 </plain></SENT>
</text></td><td align="center"><text><SENT sid="175" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="176" pm="."><plain>32–58 </plain></SENT>
</text></td><td align="center"><text><SENT sid="177" pm="."><plain>14 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="178" pm="."><plain>P5 </plain></SENT>
</text></td><td align="center"><text><SENT sid="179" pm="."><plain>87 </plain></SENT>
</text></td><td align="left"><text><SENT sid="180" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="181" pm="."><plain>Discrete hemiparesis right side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="182" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="183" pm="."><plain>67 </plain></SENT>
</text></td><td align="center"><text><SENT sid="184" pm="."><plain>24–54 </plain></SENT>
</text></td><td align="center"><text><SENT sid="185" pm="."><plain>1 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="186" pm="."><plain>P6 </plain></SENT>
</text></td><td align="center"><text><SENT sid="187" pm="."><plain>75 </plain></SENT>
</text></td><td align="left"><text><SENT sid="188" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="189" pm="."><plain>Discrete hemiparesis right side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="190" pm="."><plain>15 </plain></SENT>
</text></td><td align="center"><text><SENT sid="191" pm="."><plain>50 </plain></SENT>
</text></td><td align="center"><text><SENT sid="192" pm="."><plain>17–43 </plain></SENT>
</text></td><td align="center"><text><SENT sid="193" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="194" pm="."><plain>P7 </plain></SENT>
</text></td><td align="center"><text><SENT sid="195" pm="."><plain>86 </plain></SENT>
</text></td><td align="left"><text><SENT sid="196" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="197" pm="."><plain>Hemiparesis left side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="198" pm="."><plain>143 </plain></SENT>
</text></td><td align="center"><text><SENT sid="199" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="200" pm="."><plain>30 </plain></SENT>
</text></td><td align="center"><text><SENT sid="201" pm="."><plain>6 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="202" pm="."><plain>P8 </plain></SENT>
</text></td><td align="center"><text><SENT sid="203" pm="."><plain>67 </plain></SENT>
</text></td><td align="left"><text><SENT sid="204" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="205" pm="."><plain>Headache. </plain></SENT>
<SENT sid="206" pm="."><plain>Disturbed balance. </plain></SENT>
</text></td><td align="center"><text><SENT sid="207" pm="."><plain>20 </plain></SENT>
</text></td><td align="center"><text><SENT sid="208" pm="."><plain>87 </plain></SENT>
</text></td><td align="center"><text><SENT sid="209" pm="."><plain>35–55 </plain></SENT>
</text></td><td align="center"><text><SENT sid="210" pm="."><plain>6 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="211" pm="."><plain>P9 </plain></SENT>
</text></td><td align="center"><text><SENT sid="212" pm="."><plain>81 </plain></SENT>
</text></td><td align="left"><text><SENT sid="213" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="214" pm="."><plain>Hemiparesis left side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="215" pm="."><plain>75 </plain></SENT>
</text></td><td align="center"><text><SENT sid="216" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="217" pm="."><plain>23–59 </plain></SENT>
</text></td><td align="center"><text><SENT sid="218" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="219" pm="."><plain>P10 </plain></SENT>
</text></td><td align="center"><text><SENT sid="220" pm="."><plain>76 </plain></SENT>
</text></td><td align="left"><text><SENT sid="221" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="222" pm="."><plain>Disturbed balance. </plain></SENT>
</text></td><td align="center"><text><SENT sid="223" pm="."><plain>108 </plain></SENT>
</text></td><td align="center"><text><SENT sid="224" pm="."><plain>102 </plain></SENT>
</text></td><td align="center"><text><SENT sid="225" pm="."><plain>31–41 </plain></SENT>
</text></td><td align="center"><text><SENT sid="226" pm="."><plain>2 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="227" pm="."><plain>P11 </plain></SENT>
</text></td><td align="center"><text><SENT sid="228" pm="."><plain>65 </plain></SENT>
</text></td><td align="left"><text><SENT sid="229" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="230" pm="."><plain>Paresis right leg. </plain></SENT>
<SENT sid="231" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="232" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="233" pm="."><plain>104 </plain></SENT>
</text></td><td align="center"><text><SENT sid="234" pm="."><plain>25–29 </plain></SENT>
</text></td><td align="center"><text><SENT sid="235" pm="."><plain>8 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="236" pm="."><plain>P12 </plain></SENT>
</text></td><td align="center"><text><SENT sid="237" pm="."><plain>67 </plain></SENT>
</text></td><td align="left"><text><SENT sid="238" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="239" pm="."><plain>Hemiparesis left side. </plain></SENT>
<SENT sid="240" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="241" pm="."><plain>94 </plain></SENT>
</text></td><td align="center"><text><SENT sid="242" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="243" pm="."><plain>37–51 </plain></SENT>
</text></td><td align="center"><text><SENT sid="244" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="245" pm="."><plain>P13 </plain></SENT>
</text></td><td align="center"><text><SENT sid="246" pm="."><plain>88 </plain></SENT>
</text></td><td align="left"><text><SENT sid="247" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="248" pm="."><plain>Headache. </plain></SENT>
<SENT sid="249" pm="."><plain>Discrete dysphasia. </plain></SENT>
</text></td><td align="center"><text><SENT sid="250" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="251" pm="."><plain>43 </plain></SENT>
</text></td><td align="center"><text><SENT sid="252" pm="."><plain>28–41 </plain></SENT>
</text></td><td align="center"><text><SENT sid="253" pm="."><plain>6 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="254" pm="."><plain>P14 </plain></SENT>
</text></td><td align="center"><text><SENT sid="255" pm="."><plain>63 </plain></SENT>
</text></td><td align="left"><text><SENT sid="256" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="257" pm="."><plain>Discrete dysphasia. </plain></SENT>
<SENT sid="258" pm="."><plain>Poor motor skills right hand. </plain></SENT>
</text></td><td align="center"><text><SENT sid="259" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="260" pm="."><plain>114 </plain></SENT>
</text></td><td align="center"><text><SENT sid="261" pm="."><plain>50–61 </plain></SENT>
</text></td><td align="center"><text><SENT sid="262" pm="."><plain>8 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="263" pm="."><plain>P15 </plain></SENT>
</text></td><td align="center"><text><SENT sid="264" pm="."><plain>54 </plain></SENT>
</text></td><td align="left"><text><SENT sid="265" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="266" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="267" pm="."><plain>27 </plain></SENT>
</text></td><td align="center"><text><SENT sid="268" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="269" pm="."><plain>30–39 </plain></SENT>
</text></td><td align="center"><text><SENT sid="270" pm="."><plain>4 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="271" pm="."><plain>P16 </plain></SENT>
</text></td><td align="center"><text><SENT sid="272" pm="."><plain>76 </plain></SENT>
</text></td><td align="left"><text><SENT sid="273" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="274" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="275" pm="."><plain>39 </plain></SENT>
</text></td><td align="center"><text><SENT sid="276" pm="."><plain>22 </plain></SENT>
</text></td><td align="center"><text><SENT sid="277" pm="."><plain>22–54 </plain></SENT>
</text></td><td align="center"><text><SENT sid="278" pm="."><plain>0 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="279" pm="."><plain>P17 </plain></SENT>
</text></td><td align="center"><text><SENT sid="280" pm="."><plain>67 </plain></SENT>
</text></td><td align="left"><text><SENT sid="281" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="282" pm="."><plain>Discrete paresis left arm. </plain></SENT>
<SENT sid="283" pm="."><plain>Headache. </plain></SENT>
</text></td><td align="center"><text><SENT sid="284" pm="."><plain>112 </plain></SENT>
</text></td><td align="center"><text><SENT sid="285" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="286" pm="."><plain>18 </plain></SENT>
</text></td><td align="center"><text><SENT sid="287" pm="."><plain>12 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="288" pm="."><plain>P18 </plain></SENT>
</text></td><td align="center"><text><SENT sid="289" pm="."><plain>86 </plain></SENT>
</text></td><td align="left"><text><SENT sid="290" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="291" pm="."><plain>Hemiparesis right side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="292" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="293" pm="."><plain>144 </plain></SENT>
</text></td><td align="center"><text><SENT sid="294" pm="."><plain>32–57 </plain></SENT>
</text></td><td align="center"><text><SENT sid="295" pm="."><plain>5 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="296" pm="."><plain>P19 </plain></SENT>
</text></td><td align="center"><text><SENT sid="297" pm="."><plain>88 </plain></SENT>
</text></td><td align="left"><text><SENT sid="298" pm="."><plain>F </plain></SENT>
</text></td><td align="left"><text><SENT sid="299" pm="."><plain>Hemiparesis right side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="300" pm="."><plain>– </plain></SENT>
</text></td><td align="center"><text><SENT sid="301" pm="."><plain>118 </plain></SENT>
</text></td><td align="center"><text><SENT sid="302" pm="."><plain>23–53 </plain></SENT>
</text></td><td align="center"><text><SENT sid="303" pm="."><plain>7 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="304" pm="."><plain>P20 </plain></SENT>
</text></td><td align="center"><text><SENT sid="305" pm="."><plain>85 </plain></SENT>
</text></td><td align="left"><text><SENT sid="306" pm="."><plain>M </plain></SENT>
</text></td><td align="left"><text><SENT sid="307" pm="."><plain>Hemiparesis left side. </plain></SENT>
</text></td><td align="center"><text><SENT sid="308" pm="."><plain>105 </plain></SENT>
</text></td><td align="center"><text><SENT sid="309" pm="."><plain>67 </plain></SENT>
</text></td><td align="center"><text><SENT sid="310" pm="."><plain>24–50 </plain></SENT>
</text></td><td align="center"><text><SENT sid="311" pm="."><plain>3 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tf2"><label><sup>*</sup></label><p><text><SENT sid="312" pm="."><plain>Age, sex, main symptoms, hematoma volume, attenuation in Hounsfield units presented as an interval for patients with inhomogeneous hematomas, and midline shift. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag><p><text><SENT sid="313" pm="."><plain>Figure 4 shows the ROC curve for differentiating cSDH from HC. </plain></SENT>
<SENT sid="314" pm="."><plain>The AUC is 0.94, with a specificity of 75% at 100% sensitivity. Figure 5 shows the scatter plot. </plain></SENT>
</text></p><SecTag type="FIG"><fig id="f4" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 4.</bold></label><caption><p><text><SENT sid="315" pm="."><plain>The receiver operating characteristic curve and area under the curve (AUC) value for the leave-one-out cross-validation procedure. </plain></SENT>
</text></p></caption><graphic xlink:href="fig-4"/></fig></SecTag><SecTag type="FIG"><fig id="f5" fig-type="figure" orientation="portrait" position="float"><label><bold>FIG. 5.</bold></label><caption><p><text><SENT sid="316" pm="."><plain>Scatter plot of the classifier decision value for all subjects. </plain></SENT>
<SENT sid="317" pm="."><plain>The patients have been plotted in increasing order of total hematoma size (for patients with bilateral hematoma, the left and right side volumes were summarized) from left to right. </plain></SENT>
<SENT sid="318" pm="."><plain>The controls are plotted in chronological order from left to right. </plain></SENT>
<SENT sid="319" pm="."><plain>The dashed line shows the decision value for the classifier yielding 100% sensitivity at 75% specificity. </plain></SENT>
<SENT sid="320" pm="."><plain>The receiver operating characteristic curve (Fig. 4) was constructed by adjusting the decision value—i.e., moving the dashed line and calculating the sensitivity and specificity for all possible decision values. </plain></SENT>
</text></p></caption><graphic xlink:href="fig-5"/></fig></SecTag><p><text><SENT sid="321" pm="."><plain>Table 3 shows the results of the tests for robustness and bias of the classification. </plain></SENT>
</text></p><SecTag type="TABLE"><table-wrap id="T3" orientation="portrait" position="float"><label><sc>Table</sc> 3.</label><caption><p><text><SENT sid="322" pm="."><plain>Results for Test of Robustness and Bias of the Classification </plain></SENT>
</text></p></caption><table frame="hsides" rules="groups"><colgroup><col align="left"/><col align="left"/></colgroup><thead><tr><th align="left"><text><SENT sid="323" pm="."><plain>Data sets </plain></SENT>
</text></th><th align="center"><text><SENT sid="324" pm="."><plain>Mean AUC ± SD </plain></SENT>
</text></th></tr></thead><tbody><tr><td align="left"><text><SENT sid="325" pm="."><plain>Remove two random subjects (n = 100) </plain></SENT>
</text></td><td align="center"><text><SENT sid="326" pm="."><plain>0.90 ± 0.03 </plain></SENT>
</text></td></tr><tr><td align="left"><text><SENT sid="327" pm="."><plain>Random diagnosis (n = 100) </plain></SENT>
</text></td><td align="center"><text><SENT sid="328" pm="."><plain>0.47 ± 0.11 </plain></SENT>
</text></td></tr></tbody></table><table-wrap-foot><fn id="tf3"><p><text><SENT sid="329" pm="."><plain>AUC, area under the curve; SD, standard deviation. </plain></SENT>
</text></p></fn></table-wrap-foot></table-wrap></SecTag></sec></SecTag><SecTag type="DISCUSS"><sec sec-type="discussion" id="s008"><title><text><SENT sid="330" pm="."><plain>Discussion </plain></SENT>
</text></title><p><text><SENT sid="331" pm="."><plain>This is the first clinical study testing the validity of MWT in identifying a traumatic intracranial lesion, cSDH. </plain></SENT>
<SENT sid="332" pm="."><plain>At 100% sensitivity, the specificity was 75%, which implies that the technique could be valuable for clinical triage of patients with suspected TBI. </plain></SENT>
</text></p><p><text><SENT sid="333" pm="."><plain>The tests of robustness and bias of the classification indicate that the classifier was not overfitted to the data—i.e., the classification performance was good (AUC = 0.90 ± 0.03) for data sets (n = 100) with true diagnosis for the subjects, and classification was equal to chance (AUC ∼0.5) for data sets (n = 100) where subjects were randomly assigned to either the cSDH or HC group. </plain></SENT>
<SENT sid="334" pm="."><plain>This indicates that the MWT method with the classifier derived in this study would achieve similar performance on unseen data—i.e. on new subjects from the same populations. </plain></SENT>
</text></p><sec id="s009"><title><text><SENT sid="335" pm="."><plain>Pre-hospital screening of patients with possible TBI </plain></SENT>
</text></title><p><text><SENT sid="336" pm="."><plain>There is an obvious need for a pre-hospital screening tool to identify patients with traumatic intracranial hematomas. </plain></SENT>
<SENT sid="337" pm="."><plain>Undertriage of patients with major trauma in general, and for severe TBI in particular, is a substantial problem.2,4,18 This leads to patients with major trauma receiving definitive care at non-trauma centers or delayed care at a trauma center because of need of transfer, both associated with increased mortality.3,19 Studies show that it is common that a large proportion of patients with major trauma are first transported to non-trauma centers.3,18,20 </plain></SENT>
</text></p><p><text><SENT sid="338" pm="."><plain>Improving triage protocols to obtain higher triage accuracy for patients with suspected TBI is a major challenge. </plain></SENT>
<SENT sid="339" pm="."><plain>For example, Dehli and colleagues18 found that the triage accuracy for major trauma (ISS &gt;15) was almost the same, at an undertriage rate of 28%, also after a revision of the trauma team activation criteria, and that undertriaged patients had a higher frequency of neurosurgical injuries (p &lt; 0.05). </plain></SENT>
<SENT sid="340" pm="."><plain>Another example is the study by Ashkenazi and associates21 that evaluated whether Glasgow Coma Scale (GCS) score or the Simplified Motor Score could identify patients with severe TBI in need of neurosurgical intervention. </plain></SENT>
<SENT sid="341" pm="."><plain>The results were discouraging, because there was no statistically significant difference between the proportion of patients in need of neurosurgical procedures presenting with GCS scores of 3 to 8 and GCS scores of 9 to 14 (30% vs. 27%; p = 0.83).21 </plain></SENT>
</text></p><p><text><SENT sid="342" pm="."><plain>Near-infrared spectroscopy, as employed by the handheld Infrascanner device, measures optical density in brain regions and has been shown to be capable of identifying intracranial hematomas.6,22,23 A sensitivity of 88% and specificity of 91% was demonstrated in a bi-institutional study for hematomas larger than 3.5 mL in volume and less than 2.5 cm from the surface of the brain (n = 365 patients, whereof 50 with hematoma), which was reduced to 69% sensitivity when all hematomas were considered (96/365 patients).22 The disadvantages with the method are that near-infrared light has a short tissue penetration depth, that the current configuration of distance between light source and detector limits detection to a depth of 2–3 cm, and that the device is unable to distinguish between intracranial and extracranial lesions such as periosteal hematomas.6,23 </plain></SENT>
</text></p><p><text><SENT sid="343" pm="."><plain>Another technology suggested for detection of intracranial hemorrhage is electroencephalography (EEG). </plain></SENT>
<SENT sid="344" pm="."><plain>Prichep and coworkers8 showed in a study of 394 patients with mild TBI, of which 278 were CT-negative for hemorrhage and used as control subjects and 116 had hematomas whereof 46 were included in the study (hematoma &gt;1 mL, mean volume 16.4 mL), that a TBI-Index for EEG had a sensitivity for hematoma detection of 96% at a specificity of 44%.8 The performance was not influenced by the distance from the hematoma to the recording electrodes, nor by type or volume of hematoma. </plain></SENT>
</text></p><p><text><SENT sid="345" pm="."><plain>The TBI-Index was derived in previous studies by employing a binary classification algorithm based on selected quantitative features from an EEG limited to five electrodes placed on the forehead. </plain></SENT>
<SENT sid="346" pm="."><plain>Compared with the Infrascanner, the sensitivity for EEG appears to be higher for small bleedings, and a larger penetration depth appears to be an advantage with EEG. </plain></SENT>
<SENT sid="347" pm="."><plain>The specificity of EEG is poor, however. </plain></SENT>
</text></p><p><text><SENT sid="348" pm="."><plain>The microwave technique used in this study allows for a portable device to be used in a pre-hospital setting and to identify an intracranial hematoma at the scene of the injury, thereby enhancing early triage and allowing for more adequate early care. </plain></SENT>
<SENT sid="349" pm="."><plain>In the current pilot study, we found a specificity of 75% at a sensitivity of 100% for differentiating cSDH from HC. </plain></SENT>
<SENT sid="350" pm="."><plain>Transferring these results to a pre-hospital setting means that all patients with a significant intracranial hemorrhage would be detected. </plain></SENT>
<SENT sid="351" pm="."><plain>The rate of undertriage and the time to possible neurosurgical intervention for patients with TBI could thus be reduced. </plain></SENT>
</text></p><p><text><SENT sid="352" pm="."><plain>The cost for detecting all patients with hemorrhages would be 25% false positives—i.e., some patients would be overtriaged. </plain></SENT>
<SENT sid="353" pm="."><plain>When compared with current clinical practice, however, exemplified by the results from Lecky and associates,4 presenting an “overtriage ratio of 13:1 for neurosurgery and 4:1 for TBI,” these results are not discouraging. </plain></SENT>
<SENT sid="354" pm="."><plain>Moreover, MWT has the potential to be used in hospitals to reduce the amount of unnecessary CT scans for patients with mild TBI; to monitor patients in the neurosurgical intensive care unit—e.g., to follow the progression of hematomas.7 </plain></SENT>
</text></p><p><text><SENT sid="355" pm="."><plain>In the future, it may also be possible to image the brain and visualize hemorrhage in real time.24 Currently, MWT images do not provide detailed anatomical information compared with CT, and the time required to derive an image is too long for field use without employing a priori information about the patient, such as a previous magnetic resonance (MR) image.25 Imaging methods for MWT typically require hours to produce an image, although development of faster algorithms is ongoing.26,27 In contrast, the classification approach used in the present study is fast, giving a result within seconds. </plain></SENT>
<SENT sid="356" pm="."><plain>The main advantages with using a diagnostic algorithm is that results are presented in real time, and that no operator image interpretation is necessary. </plain></SENT>
</text></p></sec><sec id="s010"><title><text><SENT sid="357" pm="."><plain>Limitations of the study </plain></SENT>
</text></title><p><text><SENT sid="358" pm="."><plain>Because of limitations in the current study, further trials are needed before the value of MWT for pre-hospital triage of TBI can be assessed fully. </plain></SENT>
<SENT sid="359" pm="."><plain>Here, we have included only patients with cSDH, a diagnosis seldom seen in the pre-hospital emergency setting. </plain></SENT>
<SENT sid="360" pm="."><plain>Because this was the first study of patients with traumatic intracranial hemorrhage, we focused on patients who did not need immediate neurosurgical intervention. </plain></SENT>
<SENT sid="361" pm="."><plain>Obviously, for the acute trauma setting, it would be more interesting to include patients with acute hematomas. </plain></SENT>
<SENT sid="362" pm="."><plain>Further studies are under way to test the device in patients with acute hematomas (e.g., ClinicalTrials.gov, identifier: NCT02728908). </plain></SENT>
<SENT sid="363" pm="."><plain>Further, to work properly in a clinical setting, the device must also be tested for patients with other intracranial pathologies (e.g., hydrocephalus) or foreign objects implanted (e.g.. shunts or aneurysm clips), which were excluded in this investigation. </plain></SENT>
</text></p><p><text><SENT sid="364" pm="."><plain>The cSDH in the current study were all large (mean total hematoma volume [left and right side summed if bilateral] = 112 mL), because of the study design of recruiting patients admitted for surgery of cSDH, and usually acute intracranial hemorrhages are smaller. </plain></SENT>
<SENT sid="365" pm="."><plain>This raises the question whether the device would miss smaller hematomas. </plain></SENT>
<SENT sid="366" pm="."><plain>The cSDH in the current study showed a large variability in attenuation (Table 2), because of different amounts of acute blood, blood breakdown products, and membranes. </plain></SENT>
<SENT sid="367" pm="."><plain>This means that the dielectric properties of cSDH vary. </plain></SENT>
<SENT sid="368" pm="."><plain>Although the cSDH in this study are large, their heterogeneous composition may make them more difficult to detect than acute hematomas. </plain></SENT>
<SENT sid="369" pm="."><plain>Future studies are needed to assess the dielectric properties of different types of brain hemorrhage. </plain></SENT>
</text></p><p><text><SENT sid="370" pm="."><plain>Further, the concept study by Candefjord and colleagues,7 using tests on a phantom of subdural hematoma and numerical simulations, shows that the classifier requires a training data set size in the order of 100 patients and 100 control subjects to achieve high accuracy, because of high patient intervariability regarding factors such as head size.7 This indicates that a larger clinical study would allow for developing a diagnostic algorithm with capacity to detect all clinically significant hematomas, without causing a large number of false positives. </plain></SENT>
<SENT sid="371" pm="."><plain>The first clinical study showing that MWT can differentiate hemorrhagic and ischemic stroke, where hematoma volumes ranged from under 1 mL to 280 mL, further supports this notion.15 </plain></SENT>
</text></p><p><text><SENT sid="372" pm="."><plain>Numerical simulations have shown that MWT can be valuable for estimating the size and position of the hematoma.7,28 In the current study, no clear relation between decision value and hematoma volume was found (cf. Fig. 3), but such a relationship would be expected in a large clinical study of acute traumatic intracranial hemorrhage. </plain></SENT>
</text></p><p><text><SENT sid="373" pm="."><plain>Those in the HC group were classified as “healthy” because they had no significant medical history and showed no signs of neurologic disorder. </plain></SENT>
<SENT sid="374" pm="."><plain>The HC subjects, however, could still have intracranial pathology (including cSDH) because no imaging was available for comparison. </plain></SENT>
<SENT sid="375" pm="."><plain>The nature of the investigation did not allow for blinding of the patient or the examiner. </plain></SENT>
</text></p><p><text><SENT sid="376" pm="."><plain>The diagnostic algorithm has not been evaluated in an independent patient cohort in this pilot study. </plain></SENT>
<SENT sid="377" pm="."><plain>Although tests of robustness and bias have been performed and indicate that the results would be applicable to a new patient cohort, future prospective studies are needed to confirm the validity of MWT in conjunction with a diagnostic algorithm on unseen patients. </plain></SENT>
</text></p></sec></sec></SecTag><SecTag type="CONCL"><sec sec-type="conclusion" id="s011"><title><text><SENT sid="378" pm="."><plain>Conclusion </plain></SENT>
</text></title><p><text><SENT sid="379" pm="."><plain>This is the first clinical study testing the validity of MWT in detecting a traumatic intracranial lesion (cSDH). </plain></SENT>
<SENT sid="380" pm="."><plain>At 100% sensitivity, the specificity was 75%. </plain></SENT>
<SENT sid="381" pm="."><plain>The device is portable and takes measurements in 45 sec, which allows for pre-hospital use. </plain></SENT>
<SENT sid="382" pm="."><plain>The results show promise for the device to enhance triage, aid in decision making in the emergency department, and to provide additional information in monitoring of patients in the intensive care unit. </plain></SENT>
<SENT sid="383" pm="."><plain>Further investigations are under way to test the capacity of the device to identify different other intracranial lesions. </plain></SENT>
</text></p></sec></SecTag></body><back><SecTag type="COMP_INT"><sec id="s012" sec-type="COI-statement"><title>Author Disclosure Statement</title><p>M.P. is founder and main owner of Medfield Diagnostics AB. M.E. serves as unpaid consultant to Medfield Diagnostics AB. For the remaining authors, no other competing financial interests exist.</p></sec></SecTag><SecTag type="ACK_FUND"><sec id="s013" sec-type="ack"><title>Acknowledgment</title><p><text4fund><text><SENT sid="384" pm="."><plain>The authors would like to thank Dr. Andreas Bartley and Gudrun Barrows for assisting with clinical examination and data collection. </plain></SENT>
<SENT sid="385" pm="."><plain>The authors would like to thank David Andtbacka and Lukas Lönnroth for assisting with CT scan assessment. </plain></SENT>
<SENT sid="386" pm="."><plain>This study was supported by the Swedish Research Council (proj no. 921-2014-7116), the Gothenburg medical faculty (ALFGBG 542231) and the Chalmers Innovation Office (proj no. V126). </plain></SENT>
</text></text4fund></p></sec></SecTag><SecTag type="REF"><ref-list content-type="parsed"><title>References</title><ref id="B1"><text><SENT sid="387" pm="."><plain>1SeeligJ.M., BeckerD.P., MillerJ.D., GreenbergR.P., WardJ.D., and ChoiS.C. (1981). Traumatic acute subdural hematoma: major mortality reduction in comatose patients treated within four hours. N. </plain></SENT>
<SENT sid="388" pm="."><plain>Engl. </plain></SENT>
<SENT sid="389" pm="."><plain>J. </plain></SENT>
<SENT sid="390" pm="."><plain>Med. 304, 1511–15187231489 </plain></SENT>
</text></ref><ref id="B2"><text><SENT sid="391" pm="."><plain>2XiangH., WheelerK.K., GronerJ.I., Shi.J., and HaleyK.J. (2014). Undertriage of major trauma patients in the U.S. emergency departments. </plain></SENT>
<SENT sid="392" pm="."><plain>Am. </plain></SENT>
<SENT sid="393" pm="."><plain>J. </plain></SENT>
<SENT sid="394" pm="."><plain>Emerg. </plain></SENT>
<SENT sid="395" pm="."><plain>Med. 32, 997–100424993680 </plain></SENT>
</text></ref><ref id="B3"><text><SENT sid="396" pm="."><plain>3HaasB., GomezD., ZagorskiB., StukelT.A., RubenfeldG.D., and NathensA.B. (2010). Survival of the fittest: the hidden cost of undertriage of major trauma. J. </plain></SENT>
<SENT sid="397" pm="."><plain>Am. </plain></SENT>
<SENT sid="398" pm="."><plain>Coll. </plain></SENT>
<SENT sid="399" pm="."><plain>Surg. 211, 804–81121036070 </plain></SENT>
</text></ref><ref id="B4"><text><SENT sid="400" pm="."><plain>4LeckyF., RussellW., FullerG., McClellandG., PenningtonE., GoodacreS., HanK., CurranA., HollimanD., FreemanJ., ChapmanN., StevensonM., ByersS., MasonS., PotterH., CoatsT., Mackway-JonesK., PetersM., ShewanJ., and StrongM. (2016). The Head Injury Transportation Straight to Neurosurgery (HITS-NS) randomised trial: a feasibility study. Health Technol. </plain></SENT>
<SENT sid="401" pm="."><plain>Assess. 20, 1–198 </plain></SENT>
</text></ref><ref id="B5"><text><SENT sid="402" pm="."><plain>5MobashsherA.T., BialkowskiK.S., AbboshA.M., and CrozierS. (2016). Design and experimental evaluation of a non-invasive microwave head imaging system for intracranial haemorrhage detection. PLoS One 11:e015235127073994 </plain></SENT>
</text></ref><ref id="B6"><text><SENT sid="403" pm="."><plain>6Leon-CarrionJ., Dominguez-RoldanJ.M., Leon-DominguezU., and Murillo-CabezasF. (2010). The Infrascanner, a handheld device for screening in situ for the presence of brain haematomas. Brain Inj. 24, 1193–120120715889 </plain></SENT>
</text></ref><ref id="B7"><text><SENT sid="404" pm="."><plain>7CandefjordS., WingesJ., MalikA.A., YuY., RylanderT., McKelveyT., FhagerA., ElamM., and PerssonM. (2016). Microwave technology for detecting traumatic intracranial bleedings: tests on phantom of subdural hematoma and numerical simulations. Med. </plain></SENT>
<SENT sid="405" pm="."><plain>Biol. </plain></SENT>
<SENT sid="406" pm="."><plain>Eng. </plain></SENT>
<SENT sid="407" pm="."><plain>Comput. E-pub ahead of print </plain></SENT>
</text></ref><ref id="B8"><text><SENT sid="408" pm="."><plain>8PrichepL.S., NaunheimR., BazarianJ., MouldW.A., and HanleyD. (2015). Identification of hematomas in mild traumatic brain injury using an index of quantitative brain electrical activity. J. </plain></SENT>
<SENT sid="409" pm="."><plain>Neurotrauma 32, 17–2225054838 </plain></SENT>
</text></ref><ref id="B9"><text><SENT sid="410" pm="."><plain>9LinJ.C., and ClarkeM.J. Microwave imaging of cerebral edema. </plain></SENT>
<SENT sid="411" pm="."><plain>(1982). Proc. </plain></SENT>
<SENT sid="412" pm="."><plain>IEEE 70, 523–524 </plain></SENT>
</text></ref><ref id="B10"><text><SENT sid="413" pm="."><plain>10MeaneyP.M., GolnabiA.H., EpsteinN.R., GeimerS.D., FanningM.W., WeaverJ.B., and PaulsenK.D. (2013). Integration of microwave tomography with magnetic resonance for improved breast imaging. Med. </plain></SENT>
<SENT sid="414" pm="."><plain>Phys. 40, 10310124089930 </plain></SENT>
</text></ref><ref id="B11"><text><SENT sid="415" pm="."><plain>11PoplackS.P., TostesonT.D., WellsW.A., PogueB.W., MeaneyP.M., HartovA., KogelC.A., SohoS.K., GibsonJ.J., and PaulsenK.D. (2007). Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms. Radiology 243, 350–35917400760 </plain></SENT>
</text></ref><ref id="B12"><text><SENT sid="416" pm="."><plain>12PreeceA.W., CraddockI., ShereM., JonesL., and WintonH.L. (2016). MARIA M4: clinical evaluation of a prototype ultrawideband radar scanner for breast cancer detection. J. </plain></SENT>
<SENT sid="417" pm="."><plain>Med. </plain></SENT>
<SENT sid="418" pm="."><plain>Imaging (Bellingham) 3, 03350227446970 </plain></SENT>
</text></ref><ref id="B13"><text><SENT sid="419" pm="."><plain>13GabrielC., GabrielS., and CorthoutE. (1996). The dielectric properties of biological tissues: I. Literature survey. </plain></SENT>
<SENT sid="420" pm="."><plain>Phys. </plain></SENT>
<SENT sid="421" pm="."><plain>Med. </plain></SENT>
<SENT sid="422" pm="."><plain>Biol. 41, 2231–22498938024 </plain></SENT>
</text></ref><ref id="B14"><text><SENT sid="423" pm="."><plain>14GabrielS., LauR, and GabrielC. (1996). The dielectric properties of biological tissues: II. Measurements in the frequency range 10 Hz to 20 GHz. </plain></SENT>
<SENT sid="424" pm="."><plain>Phys. </plain></SENT>
<SENT sid="425" pm="."><plain>Med. </plain></SENT>
<SENT sid="426" pm="."><plain>Biol. 41, 2251–22698938025 </plain></SENT>
</text></ref><ref id="B15"><text><SENT sid="427" pm="."><plain>15PerssonM., FhagerA., TrefnaH., YuY., McKelveyT., PegeniusG., KarlssonJ.E., and ElamM. (2014). Microwave-based stroke diagnosis making global prehospital thrombolytic treatment possible. IEEE Trans. </plain></SENT>
<SENT sid="428" pm="."><plain>Biomed. </plain></SENT>
<SENT sid="429" pm="."><plain>Eng. 61, 2806–281724951677 </plain></SENT>
</text></ref><ref id="B16"><text><SENT sid="430" pm="."><plain>16DucruetA.F., GrobelnyB.T., ZachariaB.E., HickmanZ.L., DeRosaP.L., AndersenK.N., SussmanE., CarpenterA., and ConnollyE.S. (2012). The surgical management of chronic subdural hematoma. Neurosurg. </plain></SENT>
<SENT sid="431" pm="."><plain>Rev. 35, 155–16921909694 </plain></SENT>
</text></ref><ref id="B17"><text><SENT sid="432" pm="."><plain>17ParkerB.J., GünterS., and BedoJ. (2007). Stratification bias in low signal microarray studies. BMC Bioinformatics 8, 32617764577 </plain></SENT>
</text></ref><ref id="B18"><text><SENT sid="433" pm="."><plain>18DehliT., MonsenS.A., FredriksenK., and BartnesK. (2016). Evaluation of a trauma team activation protocol revision: a prospective cohort study. Scand. </plain></SENT>
<SENT sid="434" pm="."><plain>J. </plain></SENT>
<SENT sid="435" pm="."><plain>Trauma Resusc. </plain></SENT>
<SENT sid="436" pm="."><plain>Emerg. </plain></SENT>
<SENT sid="437" pm="."><plain>Med. 24, 105–11127561336 </plain></SENT>
</text></ref><ref id="B19"><text><SENT sid="438" pm="."><plain>19MacKenzieE., RivaraF., JurkovichG., NathensA., FreyK., EglestonB., SalkeverD., and ScharfsteinD. (2006). A national evaluation of the effect of trauma-center care on mortality. N. </plain></SENT>
<SENT sid="439" pm="."><plain>Engl. </plain></SENT>
<SENT sid="440" pm="."><plain>J. </plain></SENT>
<SENT sid="441" pm="."><plain>Med. 354, 366–37816436768 </plain></SENT>
</text></ref><ref id="B20"><text><SENT sid="442" pm="."><plain>20CandefjordS., BuendiaR., CaragounisE.C., SjöqvistB.A., and FagerlindH. (2016). Prehospital transportation decisions for patients sustaining major trauma in road traffic crashes in Sweden. Traffic Inj. </plain></SENT>
<SENT sid="443" pm="."><plain>Prev. 17, Suppl 1, 16–2027586097 </plain></SENT>
</text></ref><ref id="B21"><text><SENT sid="444" pm="."><plain>21AshkenaziI., SchecterW.P., PelegK., GivonA., OlshaO., Turegano-FuentesF., AlficiR., and the Israeli Trauma Group, BahouthH., BeckerA., Ben ElyM., BraslavskyA., JeroukhimovI., QarawanyM., KesselB., KleinY., LinG., MerinO., BalaM., MnouskinY., RivkindA.I., ShakedG., SofferD., SteinM., and WeissM. (2016). Glasgow Coma Scale Score in survivors of explosion with possible traumatic brain injury in need of neurosurgical intervention. JAMA Surg. 151, 954–95827409973 </plain></SENT>
</text></ref><ref id="B22"><text><SENT sid="445" pm="."><plain>22RobertsonC.S., ZagerE.L., NarayanR.K., HandlyN., SharmaA., HanleyD.F., GarzaH., Maloney-WilenskyE., PlaumJ.M., KoenigC.H., JohnsonA., and MorganT. (2010). Clinical evaluation of a portable near-infrared device for detection of traumatic intracranial hematomas. J. </plain></SENT>
<SENT sid="446" pm="."><plain>Neurotrauma 27, 1597–160420568959 </plain></SENT>
</text></ref><ref id="B23"><text><SENT sid="447" pm="."><plain>23SemenovaZh.B., MarshintsevA.V., MelnikovA.V., MeshcheryakovS.V., AdayevA.R., and LukyanovV.I. (2016). Infrascanner in the diagnosis of intracranial lesions in children with traumatic brain injuries. Brain Inj. 30, 18–2226653997 </plain></SENT>
</text></ref><ref id="B24"><text><SENT sid="448" pm="."><plain>24MohammedB.J., AbboshA.M., MustafaS., and IrelandD. (2014). Microwave system for head imaging. IEEE Transactions on Instrumentation and Measurement 63, 117–123 </plain></SENT>
</text></ref><ref id="B25"><text><SENT sid="449" pm="."><plain>25MahmoodQ., LiS, FhagerA., CandefjordS., ChodorowskiA., MehnertA., and PerssonM. (2015). A comparative study of automated segmentation methods for use in a microwave tomography system for imaging intracerebral hemorrhage in stroke patients. J. </plain></SENT>
<SENT sid="450" pm="."><plain>Electromag. </plain></SENT>
<SENT sid="451" pm="."><plain>Anal. </plain></SENT>
<SENT sid="452" pm="."><plain>Appl. 7, 152–167 </plain></SENT>
</text></ref><ref id="B26"><text><SENT sid="453" pm="."><plain>26FhagerA., PadhiS.K., and HowardJ. (2009). 3D Image reconstruction in microwave tomography using an efficient FDTD model. IEEE Ant. </plain></SENT>
<SENT sid="454" pm="."><plain>Wireless Propag Lett 8, 1353–1356 </plain></SENT>
</text></ref><ref id="B27"><text><SENT sid="455" pm="."><plain>27BonazzoliM., DoleanV., RapettiF., and TournierP.H. (2016). Parallel preconditioners for high order discretizations arising from full system modeling for brain microwave imaging. Int. </plain></SENT>
<SENT sid="456" pm="."><plain>J. </plain></SENT>
<SENT sid="457" pm="."><plain>Numer. </plain></SENT>
<SENT sid="458" pm="."><plain>Model 00, 1–10 </plain></SENT>
</text></ref><ref id="B28"><text><SENT sid="459" pm="."><plain>28CandefjordS., WingesJ., YuY., RylanderT., and McKelveyT. (2013). Microwave technology for localization of traumatic intracranial bleedings—a numerical simulation study. Presented at the 35th Annual International Conference of the IEEE EMBS, Osaka, Japan, 3–77, 2013, 1948–1951 </plain></SENT>
</text></ref></ref-list></SecTag></back></article>
